Cognitive & Nootropic

DSIP

DSIP (delta sleep-inducing peptide) is one of the oldest compounds referenced on this site — first isolated nearly five decades ago — yet its actual mechanism of action remains poorly characterized to this day.

Not currently stocked by KYIN Peptides, but available to order — see availability below.

What Is DSIP?

DSIP is a nonapeptide first isolated from rabbit cerebral venous blood in 1977 by Swiss researchers investigating blood-borne sleep factors. It is studied for its apparent influence on sleep architecture, though its name is something of a historical artifact: DSIP's actual effect on slow-wave (“delta”) sleep specifically has been inconsistent across studies, and its precise mechanism of action remains poorly characterized more than four decades after its discovery.

Research Focus

DSIP's research centers on sleep regulation, distinguishing it from the anxiolytic and neuroprotective research behind KYIN's stocked cognitive peptides, Selank and Semax. See our Cognitive & Nootropic research overview for how it fits alongside those compounds, or how Pinealon compares as another non-stocked compound in this category.

Clinical & Preclinical Trial Data

Early small-scale human trials in the late 1970s and 1980s reported real effects: a double-blind crossover study in 6 healthy volunteers found total sleep time increased 59% within 130 minutes of dosing versus placebo, and a separate double-blind study of 16 chronic insomnia patients reported higher sleep efficiency and shorter sleep latency versus placebo. Research interest declined sharply after the 1980s — the reasons are disputed, but results were inconsistent across labs and DSIP was never developed into an approved drug. No large-scale modern clinical trial exists, and DSIP is not FDA-approved for any indication.

Availability

DSIP is not part of KYIN Peptides' standard catalogue, but it is available to order — contact us directly and we'll source it for you.

⚠

Research Use Only Notice This page provides general research and educational context about DSIP only, and does not constitute medical, dosing, or human-use advice. It is not a claim about current regulatory approval, safety, or legal status in any market. Any DSIP sourced through KYIN Peptides is sold strictly for laboratory research use by qualified professionals — not for human or animal use, and not intended for diagnostic, therapeutic, or consumption purposes.

FAQ

DSIP questions

What is DSIP?

DSIP (delta sleep-inducing peptide) is a nonapeptide first isolated from rabbit cerebral venous blood in 1977 by Swiss researchers investigating blood-borne sleep factors. It is studied for its apparent influence on sleep architecture.

Does DSIP actually increase delta (slow-wave) sleep specifically?

Its name is something of a historical artifact — DSIP's actual effect on slow-wave (“delta”) sleep specifically has been inconsistent across studies, and its precise mechanism of action remains poorly characterized more than four decades after its discovery.

Has DSIP been tested in human trials?

Yes, in the late 1970s and 1980s. A double-blind crossover study in 6 healthy volunteers found total sleep time increased 59% within 130 minutes of dosing versus placebo, and a separate study of 16 chronic insomnia patients reported higher sleep efficiency and shorter sleep latency. No large-scale modern clinical trial exists, and DSIP is not FDA-approved for any indication.

Does KYIN Peptides sell DSIP?

Not as part of our standard catalogue, but yes — it's available to order. Contact us directly and we'll source it for you.

Interested in sourcing DSIP?

Contact to Order Cognitive & Nootropic Overview